De novo Stage IV Luminal Breast Cancer: Yes or No for Local Treatment? Serial Cases and Review
| Autor: | Elena Simeonovska Joveva, Marija Karakolevska-Ilova, Aleksandar Serafimov |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Bone metastasis Retrospective cohort study General Medicine medicine.disease Primary tumor Metastatic breast cancer Radiation therapy 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Breast cancer Clinical medicine 030220 oncology & carcinogenesis Internal medicine medicine business Prospective cohort study |
| Zdroj: | Open Access Macedonian Journal of Medical Sciences. 9:1-5 |
| ISSN: | 1857-9655 |
| DOI: | 10.3889/oamjms.2021.6052 |
| Popis: | BACKGROUND: Primary stage IV breast cancer accounts about of 3–5% of newly diagnosed breast cancer cases. The management of this patient subset mostly comprises systemic therapy, with additional surgery or radiotherapy to control locoregional symptoms. Some of the retrospective studies showed the benefit of locoregional treatment as the first treatment of choice for overall survival (OS), but the efficacy of primary site surgery remains controversial for OS in prospective, controlled trials. AIM: We aimed to presents series of cases with primary metastatic breast cancer with diffuse bone metastasis. MATERIALS AND METHODS: This study was serial of cases with primary metastatic breast cancer with diffuse bone metastasis and a review of the literature. All of the cases were treated with upfront surgical resection of the primary in the breast. RESULTS: During the follow-up period of 36 months, all of our patients were still alive. CONCLUSION: Retrospective studies about resection of primary tumor as the first treatment of choice are with conflicting results, which may be related to randomization bias, including different biological types of breast cancer, different metastatic sites, and patients with different menopausal status. On the other hand, prospective studies did not show any powerful results that would lead the treatment in de novo stage IV breast cancer because of few limitations such a short follow-up period (between 23 and 40 months), younger patients, ER-positive/HER2 negative tumors, and type of chemotherapy given or not upfront. The effect of upfront surgery in newly metastatic breast cancer patients is still challenging, so there is a need to identify the exact cohort of patients who could benefit from surgery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|